^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cevostamab (RG6160)

    i
    Other names: RG6160, BFCR 4350A, RG 6160, BFCR4350A, RO-7187797, RO7187797, BFCR-4350A, RG-6160, RO 7187797
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD3 agonist, FCRH5 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    PLYCOM: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Hoffmann-La Roche | Trial completion date: May 2027 --> Jul 2028 | Trial primary completion date: May 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Actemra IV (tocilizumab) • iberdomide (CC-220) • cevostamab (RG6160)
    3ms
    A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (clinicaltrials.gov)
    P1, N=120, Recruiting, Genentech, Inc. | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Elrexfio (elranatamab-bcmm) • Actemra IV (tocilizumab) • cevostamab (RG6160)
    4ms
    GO39775: Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (clinicaltrials.gov)
    P1, N=420, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)
    6ms
    LINKER-MM2: A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments (clinicaltrials.gov)
    P1, N=317, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jan 2033 --> Sep 2034 | Trial primary completion date: Mar 2027 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • Libtayo (cemiplimab-rwlc) • carfilzomib • pomalidomide • Sarclisa (isatuximab-irfc) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Ogsiveo (nirogacestat) • fianlimab (REGN3767) • Lynozyfic (linvoseltamab-gcpt) • cevostamab (RG6160)
    7ms
    A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)
    7ms
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Active, not recruiting, Genentech, Inc. | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial primary completion date
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)
    8ms
    PLYCOM: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Hoffmann-La Roche | Trial completion date: Mar 2030 --> May 2027 | Trial primary completion date: Mar 2030 --> May 2027
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Actemra IV (tocilizumab) • iberdomide (CC-220) • cevostamab (RG6160)
    8ms
    A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Hoffmann-La Roche
    New P1 trial
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)
    9ms
    GO39775: Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (clinicaltrials.gov)
    P1, N=420, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)
    9ms
    PLYCOM: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2026 --> Mar 2030 | Trial primary completion date: Mar 2026 --> Mar 2030
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Actemra IV (tocilizumab) • iberdomide (CC-220) • cevostamab (RG6160)
    10ms
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)
    11ms
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Recruiting, Genentech, Inc. | Trial completion date: Jan 2027 --> Sep 2026 | Trial primary completion date: Aug 2026 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)